What type of study is this?

This is a Case-Control Study study (also classified as: Systematic Review).

October 13, 2025Immunological MedicineOpen Access

Factors related to seroconversion of anti-cyclic citrullinated peptide antibody after the onset of rheumatoid arthritis: a case-control study and systematic review

View Full Paper

Ask AI

Bookmark

Authors

Case-control study reveals anti-CCP seroconversion links to HLA-DRB1 and bDMARD use in RA patients.

Anti-CCP seroconversion occurred in 6 out of 56 patients with rheumatoid arthritis, indicating significant disease progression.
Factors associated with seroconversion included interstitial lung disease and the presence of HLA-DRB1 shared epitope alleles.
Systematic review identified biological disease-modifying antirheumatic drugs (bDMARDs) as a relevant factor in seroconversion.
Understanding anti-CCP seroconversion may enhance recognition of seropositive rheumatoid arthritis features.

Kosumi et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark